Free cash flow remains highly inconsistent, oscillating from a negative $39.9M in 2024Q1 to a marginal positive $1.4M in 2025Q4, reflecting ongoing liquidity challenges.
| Cash from Operations | -27.04M | -45.99M | -95.21M | -156.32M | -183.94M | -192.73M | -149.68M | 205.4M | -32.26M | -34.86M |
| Operating CF Margin % | - | -16.6% | -53.2% | -91.81% | -99.26% | -124.87% | -152.14% | 241.45% | -57.95% | -90.66% |
| Operating CF Growth % | 284.8% | 51.7% | 39.09% | 15.02% | 4.56% | -28.76% | -172.87% | 736.73% | 7.46% | - |
| Net Income | -49.68M | -59.5M | -159.59M | -225.25M | -200.19M | -207.28M | -146.23M | -68.61M | -46.45M | -42.83M |
| Depreciation & Amortization | 12.74M | 0 | 19.26M | 22.23M | 28.15M | 20.98M | 8.47M | 7.79M | 6M | 5.8M |
| Stock-Based Compensation | 38.01M | 51.48M | 53.61M | 0 | 0 | 0 | 24.76M | 13.12M | 11.15M | 7.01M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 773K | -1.88M | -1.24M | 637K |
| Other Non-Cash Items | 13.47M | 19.8M | 8.97M | 92.88M | 59.65M | 50.39M | 3.34M | 43K | 5K | 6K |
| Working Capital Changes | -41.62M | -57.77M | -17.45M | -46.18M | -71.55M | -56.82M | -40.8M | 254.93M | -1.72M | -5.47M |
| Change in Receivables | -4.73M | -8.65M | -3.74M | 2.03M | -22.65M | -7.36M | 2.61M | -7.82M | 775K | -2.43M |
| Change in Inventory | -1.27M | -998K | 1.94M | -2.84M | 817K | -5.2M | -4.99M | -1.23M | -3.05M | -2.7M |
| Change in Payables | 2.82M | 665K | 671K | -5.41M | 7.11M | 3.94M | 5.25M | -2.43M | 1.87M | -1.84M |
| Cash from Investing | 21.52M | 37.95M | 77.79M | 129.65M | 2.9M | 181.21M | -117.04M | -481.7M | 736K | 36.43M |
| Capital Expenditures | -2.5M | -2.96M | -3.66M | -10.7M | -16.35M | -61.75M | -18.8M | -11.2M | -6.32M | -2.51M |
| CapEx % of Revenue | 0.84% | 1.07% | 2.05% | 6.28% | 8.82% | 40.01% | 19.11% | 13.17% | 11.35% | 6.52% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 98.24M | 470.5M | 19K | 85K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -98.24M | -470.5M | 19K | 122K |
| Cash from Financing | 32.45M | 30.4M | 241K | 2.25M | 132.26M | 27.15M | 293.59M | 319.92M | 1.25M | 50.03M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 124.38M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 24.95M | 30.4M | 241K | 2.25M | 7.89M | 26.72M | 272.16M | 320.85M | 0 | 49.83M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 7.5M | 0 | 0 | 0 | 0 | 429K | 21.43M | -934K | 1.25M | 207K |
| Net Change in Cash | 26.96M | 22.37M | -17.18M | -24.97M | -49.03M | 15.63M | 26.86M | 43.62M | -30.27M | 51.61M |
| Free Cash Flow | -29.54M | -48.95M | -98.88M | -167.02M | -200.29M | -254.47M | -168.49M | 194.2M | -38.58M | -37.36M |
| FCF Margin % | -10% | -17.67% | -55.25% | -98.09% | -108.09% | -164.87% | -171.26% | 228.28% | -69.3% | -97.18% |
| FCF Growth % | 66.72% | 50.5% | 40.8% | 16.61% | 21.29% | -51.04% | -186.76% | 603.42% | -3.25% | - |
| FCF per Share | -0.19 | -0.32 | -0.67 | -1.16 | -1.41 | -1.81 | -1.28 | 1.56 | -0.37 | -0.35 |
| FCF Conversion (FCF/Net Income) | 0.59x | 0.77x | 0.60x | 0.69x | 0.92x | 0.93x | 1.02x | -2.99x | 0.69x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Limited liquidity and dilution
According to recent financial disclosures, the persistent gap between net losses and operating cash flow suggests that Adaptive Biotechnologies continues to struggle with high non-cash expenses, as evidenced by the $11.9M in stock-based compensation recorded during the first quarter of 2026 alone.
The company's operating cash flow frequently tracks closer to net income than would be expected for a mature diagnostic firm, indicating that accruals and non-cash charges are heavily influencing the bottom line. Investors should monitor whether this reliance on equity-based compensation continues to mask the underlying cash burn required to sustain laboratory operations.
As reported in quarterly filings, the company's free cash flow trajectory remains inconsistent, oscillating from a negative $39.9M in 2024Q1 to a marginal positive $1.4M in 2025Q4, highlighting the difficulty in achieving sustainable cash generation amidst ongoing heavy investment in clinical infrastructure.
The erratic nature of these cash flows suggests that the business model is highly sensitive to the timing of milestone payments and fluctuations in diagnostic test volumes. Without a consistent trend toward positive free cash flow, the company appears to remain reliant on external capital to fund its ongoing research and development initiatives.
Based on the provided cash flow statements, working capital dynamics have been a significant drag on liquidity, most notably in 2025Q3 when a $33.9M outflow occurred, suggesting potential inefficiencies in managing receivables or inventory levels relative to the company's current revenue recognition cycle.
These periodic working capital outflows appear to exacerbate the company's cash burn, forcing management to maintain higher liquidity buffers than would otherwise be necessary. The volatility in these figures warrants further investigation into the company's collection cycles and the impact of project-based revenue on short-term cash availability.
Analysis of recent financial statements indicates that capital expenditures remain modest, with the ratio of CapEx to revenue consistently staying below 4% over the last ten quarters, suggesting that the company's primary cash drain is operational overhead rather than heavy investment in physical laboratory equipment.
The relatively low capital intensity implies that the company has already established the necessary infrastructure to support its current sequencing volume. Consequently, the primary challenge for management appears to be scaling revenue to cover fixed operating costs rather than funding further significant expansion of the physical asset base.
Quick answers to the most common questions about buying ADPT stock.
Adaptive Biotechnologies Corporation (ADPT) generated $-46.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Adaptive Biotechnologies Corporation (ADPT) reported negative free cash flow of $48.9M in 2025, indicating capital requirements exceeded cash from operations.
Adaptive Biotechnologies Corporation (ADPT) spent $3.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.